JCDSA  Vol.5 No.2 , June 2015
Treatment of Localized Vitiligo with 1% Pimecrolimus Cream versus 0.05% Clobetasol Propionate Cream—Single, Blinded, Comparative Therapeutic Trial
Abstract
Background: Calcineurin inhibitors like tacrolimus and pimecrolimus are new modality of treatment of localized vitiligo. Objective: To compare the effectiveness and side effects of 1% pimecrolimus cream in comparison with 0.05% clobetasol propionate cream as a treatment of localized type of vitiligo. Patients and Methods: Fifty two patients with localized vitiligo were included in this single, blind, comparative therapeutic trial. Full history and examination for each patient was done. Wood’s light was used when needed to confirm the diagnosis. Thirty (57.7%) were females and 22 (42.3%) males, female to male ratio of 1.36:1. Their ages ranged between 3 - 40 (13.15 ± 7.9) years, while disease duration ranged from 6 - 84 (29.62 ± 20.56) months. Total numbers of lesions were 114 lesions with a mean of 2.2 lesions per patient. The surface area of the lesions ranged between 1 - 31 (7.15 ± 6.98) cm2. Vitiliginous patches were most commonly located on face 48 (42.1%) lesions, and lower limbs 35 (30.7%) lesions. Patients were divided in to two groups according to the type of therapeutic modality. Group A consisted of 25 patients (52 lesions) receiving 1% pimecrolimus cream and Group B 27 patients (62 lesions) treated with 0.05% clobetasol propionate cream, both used twice daily. The amount of cream per area was applied according to rule of fingertip unit. Measuring the surface area of the lesions and calculating the reduction rate were done every month till the end of the 6th month. Then patients were asked to stop the use of medication to be re-evaluated again after 3 months without any treatment and to record any local or systemic side effects. Results: After 6 months of treatment there was 79.67% reduction in the surface area of lesions in Group A, while inGroup B there was 82.59% reduction in the surface area with no statistically significant difference between the two groups. The reduction rate was early as there was statistically significant reduction for both groups after one month of treatment (p value < 0.01). The reduction rates for facial lesions were more than other parts of the body. There was no significant relapse after 3 months of stopping treatment for both groups. Side effects were minimal and tolerable. Conclusions: Topical 1% pimecrolimus is as effective as clobetasol propionate in treatment of localized vitiligo affecting less than 5% of the body surface area but pimecrolimus was more preferred as the side effects of topical steroid could be avoided.

Cite this paper
Sharquie, K. , Al-Hamamy, H. , Noaimi, A. and Ali, K. (2015) Treatment of Localized Vitiligo with 1% Pimecrolimus Cream versus 0.05% Clobetasol Propionate Cream—Single, Blinded, Comparative Therapeutic Trial. Journal of Cosmetics, Dermatological Sciences and Applications, 5, 107-115. doi: 10.4236/jcdsa.2015.52013.
References

[1]   Sharquie, K.E., Mehenna, S.H., Naji, A.A. and Al-Azzawi, H. (2004) Inflammatory Changes in Vitiligo: Stage I and II Depigmentation. The American Journal of Dermatopathology, 26, 108-112.
http://dx.doi.org/10.1097/00000372-200404000-00004

[2]   Taieb, A. and Picardo, M. (2009) Clinical Practice. Vitiligo. The New England Journal of Medicine, 260, 160.
http://dx.doi.org/10.1056/NEJMcp0804388

[3]   Gawkrodger, D.J., Ormerod, A.D. and Shaw, L. (2008) Guideline for the Diagnosis and Management of Vitiligo. British Journal of Dermatology, 159, 1051-176.
http://dx.doi.org/10.1111/j.1365-2133.2008.08881.x

[4]   Sharquie, K.E., Noaimi, A.A. and Al-Mudaris, H.A. (2013) Melanocytes Transplantation in Patients with Vitiligo Using Needling Micrografting Technique. Journal of Drugs in Dermatology, 12, e74-e78.

[5]   Mahmoud, B.H., Hexsel, C.L. and Hamzavi, I.H. (2008) An Update on New and Emerging Options for the Treatment of Vitiligo. Skin Therapy Letter, 13, 1-10.

[6]   Allen, B.R., Lakhanpaul, M., Morris, A., Lateo, S., Davies, T., Scott, G., Cardno, M., Ebelin, M.E., Burtin, P. and Stephenson, T.J. (2003) Systemic Exposure, Tolerability, and Efficacy of Pimecrolimus Cream 1% in Atopic Dermatitis Patients. Archives of Disease in Childhood, 88, 969-973.
http://dx.doi.org/10.1136/adc.88.11.969

[7]   Eleston, D.M., James, W.D. and Burger, T.G. (2011) Disturbance of Pigmentation. In: Eleston, D.M., James, W.D. and Burger, T.G., Eds., Andrews Disease of the Skin, Clinical Dermatology, 11th Edition, W.B Saunders Elsevier Company, Philadelphia, 856.

[8]   Firooz, A., Solhpour, A., Gorouhi, F., Daneshpazhooh, M., Balighi, K., Farsinejad, K., Rashighi-Firoozabadi, M. and Dowlati, Y. (2006) Pimecrolimus Cream, 1%, vs. Hydrocortisone Acetate Cream, 1%, in the Treatment of Facial Seborrheic Dermatitis: A Randomized, Investigator-Blind, Clinical Trial. Archives of Dermatology, 142, 1066-1067.
http://dx.doi.org/10.1001/archderm.142.8.1066

[9]   Kreuter, A., Gambichler, T., Breuckmann, F., Pawlak, F.M., Stücker, M., Bader, A., Altmeyer, P. and Freitag, M. (2004) Pimecrolimus 1% Cream for Cutaneous Lupus Erythematosus. Journal of the American Academy of Dermatology, 51, 407-410.
http://dx.doi.org/10.1016/j.jaad.2004.01.044

[10]   Gorouhi, F., Solhpour, A., Beitollahi, J.M., Afshar, S., Davari, P., Hashemi, P., Nassiri Kashani, M. and Firooz, A. (2007) Randomized Trial of Pimecrolimus Cream versus Triamcinolone Acetonide Paste in the Treatment of Oral Lichen Planus. Journal of the American Academy of Dermatology, 57, 806-813.
http://dx.doi.org/10.1016/j.jaad.2007.06.022

[11]   Jacobi, A., Braeutigam, M., Mahler, V., Schultz, E. and Hertl, M. (2008) Pimecrolimus 1% Cream in the Treatment of Facial Psoriasis: A 16-Week Open-Label Study. Dermatology, 216, 133-136.
http://dx.doi.org/10.1159/000111510

[12]   Boone, B., Ongenae, K., Van Geel, N., Vernijns, S., De Keyser, S. and Naeyaert, J.M. (2007) Topical Pimecrolimus in the Treatment of Vitiligo. European Journal of Dermatology, 17, 55-61.

[13]   Habif, T.P. (2010) Topical Therapy and Topical Steroids. In: Habif, T.P., Ed., Clinical Dermatology: A Color Guide to Diagnosis and Therapy, 5th Edition, Mosby, Edinburgh, 79.

[14]   Rebat, M.H. and Sumayah, J.T. (2012) Disorders of Melanocytes. In: Wolff, K., Goldsmith, L.A., Katz, S.I., Gilchrest, B.A., Paller, A.S. and Leffell, D.J., Eds., Fitzpatrick’s Dermatology in General Medicine, 8th Edition, McGraw-Hill-Company, New York, 72:616-622.

[15]   Felsten, L.M., Alikhan, A. and Petronic-Rosic, V. (2011) Vitiligo: A Comprehensive Overview. Part II: Treatment Options and Approach to Treatment. Journal of the American Academy of Dermatology, 65, 493-514.
http://dx.doi.org/10.1016/j.jaad.2010.10.043

[16]   Esfandiarpour, I. (2009) The Efficacy of Pimecrolimus 1% Cream Plus Narrow-Band Ultraviolet B in the Treatment of Vitiligo: A Double-Blind Placebo-Controlled Clinical Trial. Journal of Dermatological Treatment, 20, 14-18.
http://dx.doi.org/10.1080/09546630802155057

[17]   Kovarik, C.L., Spielvogel, R.L. and Kantor, G.R. (2010) Pigmentory Disorder of the Skin. In: Elder, D.E., Johnson, B.L., Elenitsas, R. and Murphy, G.F., Eds., Levers Histopathology of the Skin,10th Edition, Lippincott-Williams & Wilkins, Philadelphia, 1575-1576.

[18]   Coskun, B., Saral, Y. and Turgut, D. (2005) Topical 0.05% Clobetasol Propionate versus 1% Pimecrolimus Ointment in Vitiligo. European Journal of Dermatology, 15, 88-91.

[19]   Lan, C.C., Chen, G.S., Chiou, M.H., Wu, C.S., Chang, C.H. and Yu, H.S. (2005) FK506 Promotes Melanocyte and Melanoblast Growth and Creates a Favourable Milieu for Cell Migration via Keratinocytes: Possible Mechanisms of How Tacrolimus Ointment Induces Repigmentation in Patients with Vitiligo. British Journal of Dermatology, 153, 498-505.
http://dx.doi.org/10.1111/j.1365-2133.2005.06739.x

[20]   Paul, C., Graeber, M. and Stuetz, A. (2000) Ascomycins: Promising Agents for the Treatment of Inflammatory Skin Diseases. Expert Opinion on Investigational Drugs, 9, 69-77.
http://dx.doi.org/10.1517/13543784.9.1.69

[21]   Shaquie, K.E., Al-Hamamy, H.R., Noaimi, A.A. and Al-Obeidy, M.H. (2014) Treatment of Vitiligo with Topical 5% Tincture Iodine and UVA Light. The American Journal of Dermatology and Venereology, 3, 75-79.

[22]   Kose, O., Arca, E. and Kurumlu, Z. (2010) Mometasone Cream versus Pimecrolimus Cream for the Treatment of Childhood Localized Vitiligo. Journal of Dermatological Treatment, 21, 133-139.
http://dx.doi.org/10.3109/09546630903266761

[23]   Boone, B., Ongenae, K., Van Geel, N., Vernijns, S., De Keyser, S. and Naeyaert, J.M. (2007) Topical Pimecrolimus in the Treatment of Vitiligo. European Journal of Dermatology, 17, 55-61.

[24]   Mayoral, F.A., Vega, J.M., Stavisky, H., McCormick, C.L. and Parneix-Spake, A. (2007) Retrospective Analysis of Pimecrolimus Cream 1% for Treatment of Facial Vitiligo. Journal of Drugs in Dermatology, 6, 517-521.

[25]   Sendur, N., Karaman, G., Sanic, N. and Savk, E. (2006) Topical Pimecrolimus: A New Horizon for Vitiligo Treatment. Journal of Dermatological Treatment, 17, 338-342.
http://dx.doi.org/10.1080/09546630601028711

[26]   Eryilmaz, A., Seckin, D. and Baba, M. (2009) Pimecrolimus: A New Choice in the Treatment of Vitiligo. Journal of the European Academy of Dermatology and Venereology, 23, 1347-1348.
http://dx.doi.org/10.1111/j.1468-3083.2009.03228.x

[27]   Seirafi, H., Farnaghi, F., Firooz, A., Vasheghani-Farahani, A., Alirezaie, N.S. and Dowlati, Y. (2007) Pimecrolimus Cream in Repigmentation of Vitiligo. Dermatology, 214, 253-259.
http://dx.doi.org/10.1159/000099592

[28]   Ho, N., Pope, E., Weinstein, M., Greenberg, S., Webster, C. and Krafchik, B.R. (2011) A Double-Blind, Randomized, Placebo-Controlled Trial of Topical Tacrolimus 0.1% vs. Clobetasol Propionate 0.05% in Childhood Vitiligo. British Journal of Dermatology, 165, 626-632.
http://dx.doi.org/10.1111/j.1365-2133.2011.10351.x

[29]   Dawid, M., Veensalu, M., Grassberger, M. and Wolff, K. (2006) Efficacy and Safety of Pimecrolimus Cream 1% in Adult Patients with Vitiligo: Results of a Randomized, Double-Blind, Vehicle-Controlled Study. Journal der Deutschen Dermatologischen Gesellschaft, 4, 942-946.
http://dx.doi.org/10.1111/j.1610-0387.2006.06124.x

[30]   Lepe, V., Moncada, B., Castanedo-Cazares, J.P., Torres-Alvarez, M.B., Ortiz, C.A. and Torres-Rubalcava, A.B. (2003) A Double-Blind Randomized Trial of 0.1% Tacrolimus vs. 0.05% Clobetasol for the Treatment of Childhood Vitiligo. Archives of Dermatology, 139, 581-585.
http://dx.doi.org/10.1001/archderm.139.5.581

[31]   Xu, A.E., Zhang, D.M., Wei, X.D., Huang, B. and Lu, L.-J. (2009) Efficacy and Safety of Tacrolimus Cream 0.1% in the Treatment of Vitiligo. International Journal of Dermatology, 48, 86-90.
http://dx.doi.org/10.1111/j.1365-4632.2009.03852.x

[32]   Hartmann, A. (2008) Occlusive Treatment Enhances Efficacy of Tacrolimus 0.1% Ointment in Adult Patients with Vitiligo: Results of a Placebo Controlled 12-Month Prospective Study. Acta Dermato Venereologica, 88, 474-479.
http://dx.doi.org/10.2340/00015555-0464

[33]   Al-Ani, Z.T. and Kubiasi, T.A. (2012) Treatment of Facial Vitiligo by 0.1% Topical Tacrolimus in the Iraqi Patients. Iraqi Journal of Community Medicine, 265-267.

[34]   Giuseppe, S., Giusto, T., Cinzia, B., Giorgia, G., Sergio De, M., Nicola, M. and Pasquale, P. (2013) Narrow Band-Ultraviolet B versus Clobetasol Propionate Foam in the Treatment of Vitiligo: A Retrospective Study. Dermatology and Therapy, 3, 95-105.
http://dx.doi.org/10.1007/s13555-013-0028-8

 
 
Top